Tuhura Biosciences Inc (HURA)

$2.60 -0.01 (-0.38%)
Market Cap 132.87M
Revenue (ttm) 0.00
Net Income (ttm) -21.68M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 190,200
Avg Vol 442,256
Day's Range N/A - N/A
Shares Out 51.10M
Stochastic %K 77%
Beta -0.01
Analysts Strong Sell
Price Target $11.31

Company Profile

TuHURA Biosciences, Inc., a clinical stage immuno-oncology company, that develops novel technologies for the treatment of cancer immunotherapies. The company's lead product candidate includes IFx2.0, an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors. It is also preparing to initiate a single randomized placebo-controlled which is in Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda; and Delta receptor technology to dev...

Industry: Biotechnology
Sector: Healthcare
Phone: 813 875 6600
Address:
10500 University Center Drive, Suite 110, Tampa, United States
BillionerOfKing
BillionerOfKing Oct. 3 at 2:32 PM
$HURA Current Stock Price: $2.62 No options data available.
0 · Reply
2TrustHim
2TrustHim Oct. 1 at 8:11 PM
$HURA I'm Liking The Volume Spike!!! https://www.marketbeat.com/stocks/NASDAQ/HURA/forecast/
0 · Reply
Love_To_Learn
Love_To_Learn Sep. 25 at 7:25 PM
$PSTV KINETA THEN TO WHO ? YMTX WHICH IS NOW TO $HURA ! ACCESSING PORTAL
1 · Reply
Love_To_Learn
Love_To_Learn Sep. 24 at 10:46 PM
$HURA dont like the route Vijay will be vetoing this proposal James I have a better option sending it to u now ! get it done asap thank u
0 · Reply
LifesGood
LifesGood Sep. 24 at 2:13 PM
$HURA
0 · Reply
demarco4ever
demarco4ever Sep. 24 at 12:39 PM
$HURA quiet before the storm! It may be a week, month or even a year but we are headed up!
1 · Reply
DarrellAnderson1026
DarrellAnderson1026 Sep. 22 at 7:55 AM
$HURA Technology services niche. Thin volume trading. No clear pattern emerging. Avoid.
0 · Reply
BillionerOfKing
BillionerOfKing Sep. 19 at 8:45 AM
$HURA trade update.
1 · Reply
CH4
CH4 Sep. 11 at 4:27 PM
$HURA loaded 2400 shares
1 · Reply
LifesGood
LifesGood Sep. 10 at 3:25 AM
$HURA
0 · Reply
Latest News on HURA
TuHURA Biosciences, Inc. to Present at the 27th Annual H.C. Wainwright Global Investment Conference

Aug 20, 2025, 8:00 AM EDT - 6 weeks ago

TuHURA Biosciences, Inc. to Present at the 27th Annual H.C. Wainwright Global Investment Conference

TuHURA Biosciences, Inc. Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

Aug 14, 2025, 4:15 PM EDT - 7 weeks ago

TuHURA Biosciences, Inc. Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

Rakovina Therapeutics Highlights Strength of Scientific Advisory Board Driving Innovation in AI-Enabled Oncology Drug Development

Jul 10, 2025, 4:00 AM EDT - 3 months ago

Rakovina Therapeutics Highlights Strength of Scientific Advisory Board Driving Innovation in AI-Enabled Oncology Drug Development

TuHURA Biosciences, Inc. Announces Inclusion in the Russell 3000® and Russell 2000® Indexes

Jul 1, 2025, 8:50 AM EDT - 3 months ago

TuHURA Biosciences, Inc. Announces Inclusion in the Russell 3000® and Russell 2000® Indexes

TuHURA Biosciences Completes Acquisition of Kineta

Jun 30, 2025, 8:50 AM EDT - 3 months ago

TuHURA Biosciences Completes Acquisition of Kineta

TuHURA Biosciences Initiates Its Phase 3 Accelerated Approval Trial of IFx-2.0 as an Adjunctive Therapy to Keytruda® (pembrolizumab) in First Line Treatment for Advanced or Metastatic Merkel Cell Carcinoma

Jun 24, 2025, 8:00 AM EDT - 3 months ago

TuHURA Biosciences Initiates Its Phase 3 Accelerated Approval Trial of IFx-2.0 as an Adjunctive Therapy to Keytruda® (pembrolizumab) in First Line Treatment for Advanced or Metastatic Merkel Cell Carcinoma

TuHURA Biosciences, Inc. and Kineta, Inc. Stockholders Approve Proposed Merger and All Related Proposals

Jun 23, 2025, 5:00 PM EDT - 3 months ago

TuHURA Biosciences, Inc. and Kineta, Inc. Stockholders Approve Proposed Merger and All Related Proposals

FDA Removes Partial Clinical Hold on TuHURA Biosciences' Phase 3 Accelerated Approval Trial for IFx-2.0 in Advanced or Metastatic Merkel Cell Carcinoma

Jun 9, 2025, 8:00 AM EDT - 4 months ago

FDA Removes Partial Clinical Hold on TuHURA Biosciences' Phase 3 Accelerated Approval Trial for IFx-2.0 in Advanced or Metastatic Merkel Cell Carcinoma

TuHURA Biosciences, Inc. Enters into $12.5 Million Equity Financing Transaction and Receives Additional $3.0 Million in Warrant Exercise Proceeds to Advance Its Pipeline of Novel Treatments to Overcome Primary Resistance to Cancer Immunotherapy

Jun 3, 2025, 9:58 AM EDT - 4 months ago

TuHURA Biosciences, Inc. Enters into $12.5 Million Equity Financing Transaction and Receives Additional $3.0 Million in Warrant Exercise Proceeds to Advance Its Pipeline of Novel Treatments to Overcome Primary Resistance to Cancer Immunotherapy

TuHURA Biosciences Presents IFx-Hu2.0 Trial-in-Progress Poster at the 2025 American Society of Clinical Oncology Annual Meeting

Jun 2, 2025, 8:03 AM EDT - 4 months ago

TuHURA Biosciences Presents IFx-Hu2.0 Trial-in-Progress Poster at the 2025 American Society of Clinical Oncology Annual Meeting

TuHURA Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides a Corporate Update

May 15, 2025, 4:10 PM EDT - 5 months ago

TuHURA Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides a Corporate Update

TuHURA Biosciences, Inc. to Present at the 3rd Annual H.C. Wainwright BioConnect Conference

May 13, 2025, 8:00 AM EDT - 5 months ago

TuHURA Biosciences, Inc. to Present at the 3rd Annual H.C. Wainwright BioConnect Conference

TuHURA Biosciences, Inc. Initiates Phase 1b/2a Study of IFx-Hu2.0 as an Adjunctive Therapy to Keytruda® (pembrolizumab) in First Line Treatment for Metastatic Merkel Cell Carcinoma of Unknown Primary Origin (MCCUP)

May 5, 2025, 8:00 AM EDT - 5 months ago

TuHURA Biosciences, Inc. Initiates Phase 1b/2a Study of IFx-Hu2.0 as an Adjunctive Therapy to Keytruda® (pembrolizumab) in First Line Treatment for Metastatic Merkel Cell Carcinoma of Unknown Primary Origin (MCCUP)

TuHURA Biosciences and Kineta Present Updated Results from Kineta's Phase I-II Study of KVA12123 and TuHURA's Mechanism of IFx-Hu2.0 Responses After Anti-PD-1 Therapy Failure in Advanced Melanoma at the American Association for Cancer Research Annual Meeting

Apr 28, 2025, 8:00 AM EDT - 5 months ago

TuHURA Biosciences and Kineta Present Updated Results from Kineta's Phase I-II Study of KVA12123 and TuHURA's Mechanism of IFx-Hu2.0 Responses After Anti-PD-1 Therapy Failure in Advanced Melanoma at the American Association for Cancer Research Annual Meeting

TuHURA Biosciences, Inc. Announces Abstracts Accepted for Poster Presentation at the 2025 AACR Annual Meeting

Apr 8, 2025, 8:00 AM EDT - 6 months ago

TuHURA Biosciences, Inc. Announces Abstracts Accepted for Poster Presentation at the 2025 AACR Annual Meeting

TuHURA Biosciences, Inc. Appoints Dr. Bertrand Le Bourdonnec as Executive Vice President, Head of Drug Discovery, Early Development, and Program Management

Apr 7, 2025, 8:24 AM EDT - 6 months ago

TuHURA Biosciences, Inc. Appoints Dr. Bertrand Le Bourdonnec as Executive Vice President, Head of Drug Discovery, Early Development, and Program Management

TuHURA Biosciences, Inc. Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update

Apr 1, 2025, 8:00 AM EDT - 6 months ago

TuHURA Biosciences, Inc. Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update

TuHURA Biosciences, Inc Appoints Craig L. Tendler M.D.

Mar 11, 2025, 8:05 AM EDT - 7 months ago

TuHURA Biosciences, Inc Appoints Craig L. Tendler M.D.

TuHURA Biosciences, Inc. to Present at the 37th Annual ROTH Conference

Mar 10, 2025, 9:00 AM EDT - 7 months ago

TuHURA Biosciences, Inc. to Present at the 37th Annual ROTH Conference

TuHURA Biosciences, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Feb 19, 2025, 9:00 AM EST - 8 months ago

TuHURA Biosciences, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VTS and HURA on Behalf of Shareholders

Dec 20, 2024, 10:18 AM EST - 10 months ago

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VTS and HURA on Behalf of Shareholders

VTS

TuHURA Biosciences, Inc. Enters into Definitive Merger Agreement to Acquire Kineta, Inc.

Dec 12, 2024, 8:45 AM EST - 10 months ago

TuHURA Biosciences, Inc. Enters into Definitive Merger Agreement to Acquire Kineta, Inc.

TuHURA Biosciences, Inc. (Nasdaq: HURA) Outlines Development Pathway for Single Phase 3 Accelerated Approval Registration Trial in First Line Treatment of Advanced or Metastatic Merkel Cell Carcinoma and Provides Business Update

Nov 25, 2024, 8:35 AM EST - 11 months ago

TuHURA Biosciences, Inc. (Nasdaq: HURA) Outlines Development Pathway for Single Phase 3 Accelerated Approval Registration Trial in First Line Treatment of Advanced or Metastatic Merkel Cell Carcinoma and Provides Business Update

TuHURA Biosciences (Nasdaq: HURA) Announces Webcast Replay of Panel Presentation at the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC

Oct 23, 2024, 8:30 AM EDT - 1 year ago

TuHURA Biosciences (Nasdaq: HURA) Announces Webcast Replay of Panel Presentation at the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC

TuHURA Biosciences (NASDAQ:HURA) to Present at the Virtual Investor "New to the Street" Event

Oct 22, 2024, 9:00 AM EDT - 1 year ago

TuHURA Biosciences (NASDAQ:HURA) to Present at the Virtual Investor "New to the Street" Event

TuHURA Biosciences Completes Merger Transaction with Kintara Therapeutics

Oct 17, 2024, 4:35 PM EDT - 1 year ago

TuHURA Biosciences Completes Merger Transaction with Kintara Therapeutics

Kintara Therapeutics Announces Correction to Prior Announcement Regarding 1-for-35 Reverse Stock Split in Connection with the Proposed Merger with TuHURA Biosciences to Close on October 18, 2024

Oct 16, 2024, 12:54 PM EDT - 1 year ago

Kintara Therapeutics Announces Correction to Prior Announcement Regarding 1-for-35 Reverse Stock Split in Connection with the Proposed Merger with TuHURA Biosciences to Close on October 18, 2024

Kintara Therapeutics Announces 1-for-35 Reverse Stock Split in Connection with the Proposed Merger with TuHURA Biosciences

Oct 16, 2024, 11:58 AM EDT - 1 year ago

Kintara Therapeutics Announces 1-for-35 Reverse Stock Split in Connection with the Proposed Merger with TuHURA Biosciences

Kintara Therapeutics Announces Correction to Prior Announcement Regarding CVR Issuance in Connection with the Proposed Merger with TuHURA Biosciences Expected to Close on October 18, 2024

Oct 15, 2024, 4:15 PM EDT - 1 year ago

Kintara Therapeutics Announces Correction to Prior Announcement Regarding CVR Issuance in Connection with the Proposed Merger with TuHURA Biosciences Expected to Close on October 18, 2024

Kintara Therapeutics Announces Record Date for CVR Issuance in Connection with the Proposed Merger with TuHURA Biosciences Expected to Close on October 18, 2024

Oct 14, 2024, 8:30 AM EDT - 1 year ago

Kintara Therapeutics Announces Record Date for CVR Issuance in Connection with the Proposed Merger with TuHURA Biosciences Expected to Close on October 18, 2024

Kintara Therapeutics Announces Fiscal 2024 Financial Results and Provides Corporate Update

Oct 8, 2024, 7:00 AM EDT - 1 year ago

Kintara Therapeutics Announces Fiscal 2024 Financial Results and Provides Corporate Update

Kintara Therapeutics Announces Adjournment of Special Meeting of Stockholders until October 4, 2024

Sep 20, 2024, 9:25 AM EDT - 1 year ago

Kintara Therapeutics Announces Adjournment of Special Meeting of Stockholders until October 4, 2024

Kintara Therapeutics Reminds Stockholders to Vote by Thursday to Allow for Completion of the Proposed Merger with TuHURA Biosciences

Sep 18, 2024, 8:30 AM EDT - 1 year ago

Kintara Therapeutics Reminds Stockholders to Vote by Thursday to Allow for Completion of the Proposed Merger with TuHURA Biosciences

Kintara Therapeutics Provides Update on Corporate Developments and REM-001 Clinical Study

Sep 11, 2024, 8:30 AM EDT - 1 year ago

Kintara Therapeutics Provides Update on Corporate Developments and REM-001 Clinical Study

Kintara Therapeutics to Hold Special Meeting of Stockholders to Allow for Completion of the Proposed Merger with TuHURA Biosciences, Inc.

Sep 9, 2024, 8:30 AM EDT - 1 year ago

Kintara Therapeutics to Hold Special Meeting of Stockholders to Allow for Completion of the Proposed Merger with TuHURA Biosciences, Inc.

TuHURA Biosciences and Kintara Therapeutics Announce Kineta Inc. Reopens Enrollment for VISTA-101 Clinical Trial Evaluating KVA12123 in Patients with Advanced Solid Tumor Cancer

Aug 19, 2024, 9:00 AM EDT - 1 year ago

TuHURA Biosciences and Kintara Therapeutics Announce Kineta Inc. Reopens Enrollment for VISTA-101 Clinical Trial Evaluating KVA12123 in Patients with Advanced Solid Tumor Cancer

TuHURA Biosciences Enters into Exclusivity and Right of First Offer Agreement for Kineta, Inc.'s KVA12123 Novel anti-VISTA Checkpoint Inhibitor

Jul 8, 2024, 6:30 AM EDT - 1 year ago

TuHURA Biosciences Enters into Exclusivity and Right of First Offer Agreement for Kineta, Inc.'s KVA12123 Novel anti-VISTA Checkpoint Inhibitor

Kintara Therapeutics and TuHURA Biosciences Provide Update on Recent Corporate and Clinical Advancements and Outline Near Term Milestones

Jul 1, 2024, 8:35 AM EDT - 1 year ago

Kintara Therapeutics and TuHURA Biosciences Provide Update on Recent Corporate and Clinical Advancements and Outline Near Term Milestones

TuHURA Biosciences and Kintara Therapeutics Announce Positive Results from Phase 1b Trial of IFx-2.0, a Novel Personalized Cancer Vaccine, in Checkpoint Inhibitor Resistant Advanced Merkel Cell Carcinoma (MCC) and Cutaneous Squamous Cell Carcinoma (cSCC)

Jun 3, 2024, 8:35 AM EDT - 1 year ago

TuHURA Biosciences and Kintara Therapeutics Announce Positive Results from Phase 1b Trial of IFx-2.0, a Novel Personalized Cancer Vaccine, in Checkpoint Inhibitor Resistant Advanced Merkel Cell Carcinoma (MCC) and Cutaneous Squamous Cell Carcinoma (cSCC)

Kintara Therapeutics Announces Fiscal 2024 Third Quarter Financial Results

May 14, 2024, 4:45 PM EDT - 1 year ago

Kintara Therapeutics Announces Fiscal 2024 Third Quarter Financial Results

KINTARA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Kintara Therapeutics, Inc. - KTRA

Apr 5, 2024, 1:31 PM EDT - 1 year ago

KINTARA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Kintara Therapeutics, Inc. - KTRA

Kintara Therapeutics and TuHURA Biosciences Enter into Definitive Merger Agreement

Apr 3, 2024, 7:00 AM EDT - 1 year ago

Kintara Therapeutics and TuHURA Biosciences Enter into Definitive Merger Agreement

Kintara Therapeutics Announces Expansion of REM-001 Clinical Study to Include Patients on Pembrolizumab

Mar 27, 2024, 9:00 AM EDT - 1 year ago

Kintara Therapeutics Announces Expansion of REM-001 Clinical Study to Include Patients on Pembrolizumab

Kintara Therapeutics Announces Fiscal 2024 Second Quarter Financial Results and Provides Corporate Update

Feb 14, 2024, 4:07 PM EST - 1 year ago

Kintara Therapeutics Announces Fiscal 2024 Second Quarter Financial Results and Provides Corporate Update

Kintara Therapeutics Announces Initiation of REM-001 Clinical Trial for the Treatment of Cutaneous Metastatic Breast Cancer

Feb 12, 2024, 9:00 AM EST - 1 year ago

Kintara Therapeutics Announces Initiation of REM-001 Clinical Trial for the Treatment of Cutaneous Metastatic Breast Cancer

Top 5 Health Care Stocks That Could Lead To Your Biggest Gains in January - Corcept Therapeutics (NASDAQ:CORT), Kintara Therapeutics (NASDAQ:KTRA)

Jan 2, 2024, 7:06 AM EST - 1 year ago

Top 5 Health Care Stocks That Could Lead To Your Biggest Gains in January - Corcept Therapeutics (NASDAQ:CORT), Kintara Therapeutics (NASDAQ:KTRA)

CORT MIST RPID

Top 3 Health Care Stocks That Are Preparing To Pump This Month - Durect (NASDAQ:DRRX), Aadi Bioscience (NASDAQ:AADI)

Dec 18, 2023, 7:39 AM EST - 1 year ago

Top 3 Health Care Stocks That Are Preparing To Pump This Month - Durect (NASDAQ:DRRX), Aadi Bioscience (NASDAQ:AADI)

DRRX

BillionerOfKing
BillionerOfKing Oct. 3 at 2:32 PM
$HURA Current Stock Price: $2.62 No options data available.
0 · Reply
2TrustHim
2TrustHim Oct. 1 at 8:11 PM
$HURA I'm Liking The Volume Spike!!! https://www.marketbeat.com/stocks/NASDAQ/HURA/forecast/
0 · Reply
Love_To_Learn
Love_To_Learn Sep. 25 at 7:25 PM
$PSTV KINETA THEN TO WHO ? YMTX WHICH IS NOW TO $HURA ! ACCESSING PORTAL
1 · Reply
Love_To_Learn
Love_To_Learn Sep. 24 at 10:46 PM
$HURA dont like the route Vijay will be vetoing this proposal James I have a better option sending it to u now ! get it done asap thank u
0 · Reply
LifesGood
LifesGood Sep. 24 at 2:13 PM
$HURA
0 · Reply
demarco4ever
demarco4ever Sep. 24 at 12:39 PM
$HURA quiet before the storm! It may be a week, month or even a year but we are headed up!
1 · Reply
DarrellAnderson1026
DarrellAnderson1026 Sep. 22 at 7:55 AM
$HURA Technology services niche. Thin volume trading. No clear pattern emerging. Avoid.
0 · Reply
BillionerOfKing
BillionerOfKing Sep. 19 at 8:45 AM
$HURA trade update.
1 · Reply
CH4
CH4 Sep. 11 at 4:27 PM
$HURA loaded 2400 shares
1 · Reply
LifesGood
LifesGood Sep. 10 at 3:25 AM
$HURA
0 · Reply
jayyflash
jayyflash Sep. 9 at 4:04 PM
$HURA There is no reason for this to be shorted down by 8% today to $2.31 other than manipulation. Just stealing people's money and getting away with it and How is this stock suppose to be at a buy Rating of $15 but can't even get past $3 without being shorted down to $2 range. Make them reap what they sow
0 · Reply
Dkll303
Dkll303 Sep. 9 at 10:21 AM
$HURA wainwright is the lowest of low firms
0 · Reply
deyoart
deyoart Sep. 7 at 11:12 PM
$HURA Any info on the status of the CVRs or any prognostications?
2 · Reply
JavierLara
JavierLara Sep. 5 at 1:16 PM
$HURA
1 · Reply
LifesGood
LifesGood Sep. 5 at 1:13 AM
$HURA
0 · Reply
jayyflash
jayyflash Sep. 4 at 4:42 PM
$HURA Hopefully Good News at this Presentation in 4 days:a Phase 3 immune-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that management will present at the 27th Annual H.C. Wainwright Global Investment Conference taking place September 8-10, 2025 in New York City.
0 · Reply
cranio_verde
cranio_verde Sep. 1 at 9:51 PM
$HURA :
1 · Reply
zire200402
zire200402 Sep. 1 at 9:47 AM
$HURA no rush
0 · Reply
LifesGood
LifesGood Aug. 30 at 7:19 PM
$HURA
0 · Reply
Love1010
Love1010 Aug. 30 at 5:13 PM
$HURA good chance you could see zero in this one!
0 · Reply
jayyflash
jayyflash Aug. 28 at 3:40 PM
$HURA Ok. What is wrong with this stock? It has had a $15 Buy rating for more than 8 months ad yet as soon as it gets past $3, someone shorts the price down to be under $3 every single day. If a stock has no growth in that many quarters of the year and manipulated to stay under a certain price for that long, it needs to be questioned on what is being done to it.
2 · Reply
cranio_verde
cranio_verde Aug. 28 at 1:53 PM
$HURA
0 · Reply